Medizinische Hochschule Hannover Trials

Medizinische Hochschule Hannover	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Qu, Xiujuan

HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting

918

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene, Ltd.

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

12/24

07/25

NCT06085365: Effects of Immunonutrition on the Improvement of Postoperative Adjuvant Chemotherapy Related Adverse Reactions in Patients With Gastrointestinal Tumors

Recruiting

324

RoW

Immunonutrition （Su yusu), fluorouracil based chemotherapy regimens

China Medical University, China

Gastrointestinal Tumors, Immunonutrition, Postoperative Adjuvant Chemotherapy

07/24

12/24

MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting

400

Europe, Canada, Japan, US, RoW

tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil

Seagen Inc., Merck Sharp & Dohme LLC

Colorectal Neoplasms

08/25

04/28

NCT04848753: Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Active, not recruiting

663

RoW

Toripalimab combined with cisplatin and paclitaxel, Placebo combined with cisplatin and paclitaxel

Shanghai Junshi Bioscience Co., Ltd.

Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

05/27

ALTER-C003, NCT04970914: Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:

Recruiting

RoW

Anlotinib, anlotinib hydrochloride, Penpulimab, AK105

Peking Union Medical College Hospital

Colorectal Cancer

08/22

08/23

NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Recruiting

RoW

Infigratinib, BGJ398, BBP-831

LianBio LLC

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

04/25

12/25

NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Active, not recruiting

103

RoW

Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan

Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany

BRAF V600E, Metastatic Colorectal Cancer

12/23

01/25

SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Recruiting

278

Europe, RoW

SKB264, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate

Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Non-small Cell Lung Cancer

12/25

08/26

TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting

1/2

320

RoW

TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab

Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb

Advanced Cancer

08/24

11/24

NCT06255262: Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Not yet recruiting

1/2

RoW

Surufatinib, SULANDA, HMPL-012, Durvalumab, IMFINZI

China Medical University, China

Biliary Tract Cancer

10/25

12/25

NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

Recruiting

1/2

156

RoW

JS111(AP-L1898 Capsules)

Suzhou Junjing BioSciences Co., Ltd.

Lung Cancer

06/24

08/24

NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Recruiting

1/2

192

RoW

CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC)

CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University

Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma

06/24

06/38

NCT06010901: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

Recruiting

RoW

TQB2618 injection, Penpulimab injection, Anlotinib hydrochloride capsules

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Colorectal Cancer

03/25

07/25

NCT06050980: Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation

Recruiting

220

RoW

HSK40118

Haisco Pharmaceutical Group Co., Ltd.

NSCLC

08/25

06/27

NCT06115902: A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

Recruiting

150

RoW

TQB2102 for injection

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Breast Cancer

12/25

12/26

NCT04835324: Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study

Active, not recruiting

N/A

650

RoW

Chinese Academy of Medical Sciences, Beijing Hospital, Jiangsu Cancer Institute & Hospital, The Affiliated Hospital of Qingdao University, Shanxi Province Cancer Hospital, Affiliated Hospital of Hebei University, Shandong Cancer Hospital and Institute, The First Affiliated Hospital of Zhengzhou University, Hebei Medical University Fourth Hospital, First Hospital of China Medical University

Advanced Colorectal Cancer

02/22

10/22

NCT06463548: Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

Not yet recruiting

N/A

RoW

irinotecan hydrochloride liposome injection, duoenyi, Capecitabine, Kapeitabin, Lenvatinib, lunfatini

Yunpeng Liu, CSPC Ouyi Pharmaceutical Co., Ltd.

Biliary Tract Carcinoma

12/25

12/26

NCT06480864: Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Small Cell Lung Cancer

Not yet recruiting

N/A

RoW

Adebrelimab Injection, Apatinib Mesylate Tablets, Carboplatin, Cisplatin, Etoposide

Yunpeng Liu, Jiangsu HengRui Medicine Co., Ltd.

Small Cell Lung Cancer

08/25

08/26

Heuser, Michael

NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting

882

Europe

Cytarabine, Daunorubicin, CPX-351

University of Ulm, Jazz Pharmaceuticals

Acute Myeloid Leukemia

03/24

NCT04628026: Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Recruiting

650

Europe

Venetoclax, Placebo, Standard chemotherapy, Autologous stem cell transplantation, Allogeneic stem cell transplantation

University of Ulm, Stichting Hemato-Oncologie voor Volwassenen Nederland

Acute Myeloid Leukemia, Myelodysplastic Syndromes

02/25

02/31

KOMET-001, NCT04067336: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting

1/2

199

Europe, Canada, US

Ziftomenib

Kura Oncology, Inc.

Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia

09/24

09/25

VENreg, NCT03662724: Venetoclax Registry

Recruiting

N/A

100

Europe

Venetoclax, Venclyxto

Hannover Medical School

Acute Myeloid Leukemia

11/21

11/25

NCT05290662: Registry of Patients Having Received oNKord®

Recruiting

N/A

Europe

oNKord®, Cyclophosphamide/Fludarabine (Cy/Flu)

Glycostem Therapeutics BV

AML

03/28

Susen, Sophie

NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting

Europe, US, RoW

von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII

Baxalta now part of Shire, Takeda Development Center Americas, Inc.

Von Willebrand Disease

01/25

THROMBO-VAXCOV, NCT04889326: Collection of the Thrombo-VaxCov Cohort

Recruiting

N/A

100

Europe

Retrospective data and biological samples

University Hospital, Lille

Covid19, SARS-CoV Infection, Venous Thrombosis, Thrombocytopenia, Vaccination; Complications

05/23

NCT05376462: Quantra® System With the QStat® Cartridge in Trauma

Completed

N/A

Europe

Quantra System with the QStat Cartridge, Standard Laboratory Tests

HemoSonics LLC, University Hospital, Lille

Trauma, Coagulation Defect; Bleeding

01/24

PHILEOS, NCT04384341: Haemophilia and Bone Loss - Study

Recruiting

N/A

480

Europe

Bone densitometry (BMD), Blood sampling for patients only

Centre Hospitalier Universitaire de Saint Etienne, Ministry of Health, France

Hemophilia

12/24

03/25

BÃ¼chner, Andreas

NCT06301568: Retrospective Analysis of Long-term Speech Performance in Cochlear Implant Recipients Using Electro-acoustic Stimulation

Recruiting

N/A

Europe

Advanced Bionics AG

Cochlear Hearing Loss

04/24

05/24

NCT06301581: Retrospective Analysis of Speech Performance Using the HiRes Ultra and HiRes Ultra 3D Cochlear Implant

Recruiting

N/A

200

Europe

Advanced Bionics AG

Cochlear Hearing Loss

12/25

LOTOS, NCT06343571: Longitudinal Outcomes in MED-EL Cochlear Implant Recipients Using a FLEX Electrode

Active, not recruiting

N/A

2000

Europe

MED-EL Elektromedizinische Geräte GesmbH

Cochlear Implants

08/24

RND3, NCT04918654: Automatic Sound Management 3.0 in a Single-unit Audio Processor

Completed

N/A

Europe

MED-EL Elektromedizinische Geräte GesmbH, Hannover Medical School

Cochlear Implants

12/23

Hillemanns, Peter

ECLAT, NCT03438474: Endometrial Cancer Lymphadenectomy Trial

Recruiting

N/A

640

Europe, Japan, RoW

Standard surgical procedure for endometrial cancer, systematic lymphadenectomy (LNE)

Philipps University Marburg Medical Center, German Cancer Aid

Cancer of Endometrium Stage I, Cancer of Endometrium Stage II

02/28

02/29

Schmitto, Jan

EuroECMO-COVID, NCT04366921: European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO

Recruiting

N/A

150

Europe, RoW

Maastricht University Medical Center, European chapter of the Extracorporeal Life Support Organization, Erasmus Medical Center, Leiden University Medical Center, UMC Utrecht, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Papa Giovanni XXIII Hospital, Niguarda Hospital, Ospedale San Donato, Ospedale S. Giovanni Bosco, IRCCS Policlinico S. Matteo, The Mediterranean Institute for Transplantation and Advanced Specialized Therapies, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Ospedale dell'Angelo, Venezia-Mestre, University Hospital, Udine, Italy, San Gerardo Hospital, Ospedali Riuniti Ancona, San Camillo Hospital, Rome, San Giorgio Clinic, GVM Care & Research, San Raffaele University Hospital, Italy, Ospedale San Bortolo di Vicenza, Klinik Hirslanden, Zurich, University of Zurich, Cardiocentro Ticino, Vilnius University Hospital Santaros Klinikos, Universitätsklinikum Düsseldorf, Klinikum Nürnberg, Hannover Medical School, Heart Center Leipzig - University Hospital, University Hospital Regensburg, University Hospital, Essen, German Heart Center, University Hospital, Aachen, University Heart Center Freiburg - Bad Krozingen, Klinikum Kassel, General University Hospital, Prague, Universitaire Ziekenhuizen Leuven, Onze Lieve Vrouwziekenhuis Aalst, Erasme University Hospital, University Hospital, Antwerp, Hôpital Civil Marie Curie de Charleroi, University Hospital, Ghent, Centre Hospitalier Universitaire Saint Pierre, Hospital Vall d'Hebron, Hospital Universitario Ramon y Cajal, Hospital Miguel Servet, Henri Mondor University Hospital, Hospices Civils de Lyon, Pitié-Salpêtrière Hospital, Rennes University Hospital, Guy's and St Thomas' NHS Foundation Trust, Karolinska University Hospital, Hospital Sao Joao, Medical University of Warsaw, Universitätskliniken Innsbruck, Medical University of Vienna, University Hospital, Alexandroupolis, Novosibirsk City Hospital #2, City Clinical Hospital No. 67, Moscow, Russia, City Hospital No 40, Saint Petersburg, Russia, Krasnodar Regional Hospital no 1, Kemerovo Regional Clinical Cardiological Center named after academician L.S. Barbarash, City Hospital No 41, Ekaterinburg, Russia, G. Pasquinucci Heart Hospital, Massa, Charles University, Czech Republic, University Hospital, Bordeaux, Bambino Gesù Hospital and Research Institute, Policlinico Hospital Milan, Gaslini Children's Hospital, Children's Medical Hospital, University of Essen, Essen, Germany, University Hospital, Geneva, Newcastle-upon-Tyne Hospitals NHS Trust, Paediatric Intensive Care Glasgow, Paris South University Hospitals, University of Groningen, Great Ormond Street Hospital for Children NHS Foundation Trust, Hospital Sant Joan de Deu, Heim Pal Children's Hospital, University Hospital, Montpellier, Royal Brompton & Harefield NHS Foundation Trust, Lund University Hospital, Landesklinikum Sankt Polten, Chelyabinsk Regional Clinical Hospital, ECMO Centers Israel, Copenhagen University Hospital at Herlev, Ospedale M. Bufalini Cesena, A.O.U. Città della Salute e della Scienza - Molinette Hospital, Mauriziano Umberto I Hospital, University of Bern, University Hospital, Basel, Switzerland, University of Lausanne Hospitals, University Hospital Tuebingen, Universitätsklinikum Köln, Chirec, Universitair Ziekenhuis Brussel, Centre Hospitalier Universitaire de Liège, La Louvière Hopital, Leicester Royal Infirmary NHS Trust

COVID, SARS-CoV-2, ARDS, Human, Refractory Hypoxemia, Cardiogenic Shock, Septic Shock, Extracorporeal Membrane Oxygenation

04/22

NCT02387112: Early Versus Emergency Left Ventricular Assist Device Implantation in Patients Awaiting Cardiac Transplantation

Active, not recruiting

N/A

102

Europe

Early VAD implantation

German Heart Institute, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Helmholtz Zentrum München, University Medicine Greifswald, University of Göttingen

End Stage Heart Disease

03/24

12/24

NCT05077124: Safe and Timely Antithrombotic Removal (STAR) Registry

Recruiting

N/A

500

Europe

CytoSorb

CytoSorbents, Inc

Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative

09/25

WeiÃŸenborn, Karin

ASTRO-DE, NCT05127941: Andexanet Alfa: Non-interventional Study in Stroke Units in Germany (DE)

Active, not recruiting

N/A

141

Europe

University Hospital, Essen

Intracranial Hemorrhages

07/24

12/24

Find-AF2, NCT04371055: Intensive Rhythm Monitoring to Decrease Ischemic Stroke and Systemic Embolism - the Find-AF 2 Study

Recruiting

N/A

5200

Europe

7-day Holter ECG, Implantable cardiac monitor, Standard of care

University of Leipzig, Johannes Gutenberg University Mainz

Ischemic Stroke, Atrial Fibrillation

06/26

12/26

Dopfer, Christian

TRACK-CF, NCT02270476: Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening

Recruiting

N/A

200

Europe

Heidelberg University, German Center for Lung Research

Cystic Fibrosis Lung Disease

12/30

Hohmann, Stephan

RAVENTA, NCT03867747: Radiosurgery for the Treatment of Refractory Ventricular Extrasystoles and Tachycardias

Active, not recruiting

N/A

Europe

Cardiac Radiosurgery

University Hospital Schleswig-Holstein, Universitätsmedizin Mannheim

Ventricular Tachycardia

11/23

10/24

Veltmann, Christian

NCT02880618: BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction

Recruiting

N/A

500

Europe

Barostim Neo™ System

CVRx, Inc.

Heart Failure

07/24

NCT06048731: Enlighten Study: The EV-ICD Post Approval Registry

Recruiting

N/A

1000

Europe, Canada, US, RoW

Defibrillation using EV-ICD

Medtronic

Ventricular Arrhythmia, Tachycardia

05/30

10/37

Siegmund, Britta

ASPIRE, NCT04118088: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Active, not recruiting

Europe, RoW

Darvadstrocel, Alofisel, Cx601

Takeda, Takeda Development Center Americas, Inc.

Crohn's Disease, Complex Perianal Fistula

03/26

FRESCO, NCT03843385: Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis

Recruiting

174

Europe

encapsulated faecal microbiota filtrate, FMFT, encapsulated faecal microbiota, FMT, Placebo, Encapsulated sterile saline

Tabitha Heller, German Federal Ministry of Education and Research

Ulcerative Colitis, Inflammatory Bowel Diseases

01/25

07/26

NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting

612

Europe, Canada, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

12/24

02/25

NCT05535946: ABTECT - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

06/26

LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis

Recruiting

1063

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Ulcerative Colitis

07/26

12/27

EUPHORIA, NCT04456400: Enhancing Ultrasound & Photoacoustic for Recognition of Intestinal Abnormalities

Suspended

N/A

540

Europe

Multispectral Optoacoustic Tomography (MSOT)

iThera Medical GmbH, European Commission

Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease

12/23

04/24

Werfel, Thomas

TREATgermany, NCT03057860: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis

Recruiting

N/A

2800

Europe

No study intervention

Technische Universität Dresden

Moderate-to-severe Atopic Dermatitis

12/26

Hansen, Gesine

NEST, NCT05429047: Priming of the NEonatal Immune System by Transfer of Maternal Immunity

Recruiting

N/A

560

Europe

Tozinameran, COVID-19, No SARS-CoV-2 exposure

Hannover Medical School, Else Kröner Fresenius Foundation

COVID-19, Maternal Vaccine Exposure, Respiratory Infections in Children

04/23

12/23

ALLIANCE, NCT02496468: Pediatric Arm of DZL All Age Asthma Cohort

Recruiting

N/A

1500

Europe

LMU Klinikum, German Federal Ministry of Education and Research, German Center for Lung Research, Comprehensive Pulmonary Center Munich, Airway Research Center North, Biomedical Research in Endstage and Obstructive Lung Disease Hannover, Translational Lung Research Center Heidelberg, Universities of Giessen and Marburg Lung Center

Asthma, Wheeze, Hypersensitivity, Endophenotype

12/23

pedCAPNETZ, NCT04047108: - Community Acquired Pneumonia (CAP) in Childhood and Adolescence

Recruiting

N/A

1000

Europe

Hannover Medical School

Community-acquired Pneumonia

12/23

Held, Gerhard

DaunoDouble, NCT02140242 / 2013-003191-12: Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML

Completed

721

Europe, RoW

study part 1 - dose daunorubicin, induction cycles

Technische Universität Dresden, University Hospital Dresden, Masaryk University

Leukemia, Myelocytic, Acute

04/22

NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting

882

Europe

Cytarabine, Daunorubicin, CPX-351

University of Ulm, Jazz Pharmaceuticals

Acute Myeloid Leukemia

03/24

OPTIMAL>60, NCT01478542 / 2010-019587-36: / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

	ASH 2014
	Nov 2014 - Nov 2014: ASH 2014
	P3 enrollment initiation in 1st line, adult NHL pts
	Nov 2011 - Nov 2011: P3 enrollment initiation in 1st line, adult NHL pts

Completed

1152

Europe

Conventional Vincristine, Liposomal Vincristine, Ricover-scheme rituximab, optimised rituximab-schedule

Universität des Saarlandes, German High-Grade Non-Hodgkin's Lymphoma Study Group, Spectrum Pharmaceuticals, Inc

CD20+ Aggressive B-Cell Lymphoma

01/24

NIVEAU, NCT03366272 / 2016-002272-27: Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

Active, not recruiting

2/3

348

Europe, RoW

Nivolumab, Rituximab, Gemcitabine, Oxaliplatin

Universität des Saarlandes, Bristol-Myers Squibb, Lymphoma Study Association, University of Leipzig

Lymphoma, Non-Hodgkin

11/24

AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project

Recruiting

N/A

Europe

University of Ulm

Acute Myeloid Leukemia (AML), Higher Risk Myelodysplastic Syndromes (MDS With Excess Blasts 2)

NCT03188874: Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

Recruiting

N/A

15000

Europe

Technische Universität Dresden

Acute Myeloid Leukemia (AML)

09/30

Ringshausen, Felix C

CHOICES, NCT06468527: Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF

Recruiting

Europe

Diponecaftor, Placebo

Kors van der Ent, European Union

Cystic Fibrosis

04/25

06/25

PROGNOSIS, NCT02574143: The PROspective German NOn-CF bronchiectaSIS Patient Registry

Recruiting

N/A

750

Europe

Hannover Medical School, CAPNETZ Stiftung, German Center for Lung Research

Bronchiectasis

11/20

07/21

CAR-CF, NCT05012306: Covid-19 Antibody Responses in Cystic Fibrosis

Active, not recruiting

N/A

500

Europe

Universitätsklinikum Köln

Cystic Fibrosis

05/24

Berardi, Rossana

HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Recruiting

650

Europe, Canada, Japan, US, RoW

Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo

Seagen Inc., Merck Sharp & Dohme LLC

HER2 Positive Breast Cancer

10/24

06/27

ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer

Active, not recruiting

Europe, Canada, Japan, US, RoW

Niraparib, Placebo

GlaxoSmithKline

Neoplasms, Breast

03/25

08/29

KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Active, not recruiting

407

Europe, US, RoW

IO102-IO103, Pembrolizumab

IO Biotech, Syneos Health, Merck Sharp & Dohme LLC

Metastatic Melanoma, Unresectable Melanoma

07/25

09/27

FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting

200

Europe, US, RoW

Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice

TransThera Sciences (Nanjing), Inc.

Cholangiocarcinoma

05/26

08/26

PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Recruiting

600

Europe, Canada, US, RoW

Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere

OncoC4, Inc., BioNTech SE

Non Small Cell Lung Cancer

06/26

06/27

Be6A Lung-01, NCT06012435: A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Recruiting

600

Europe, Canada, Japan, US, RoW

sigvotatug vedotin, SGN-B6A, docetaxel

Seagen Inc.

Carcinoma, Non-Small-Cell Lung

07/26

07/28

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

6000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

DENIM, NCT03610360 / 2017-001774-41: DENdritic Cell Immunotherapy for Mesothelioma

Completed

2/3

176

Europe

MesoPher

Amphera BV, TMC Pharma

Mesothelioma

06/22

COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy

Active, not recruiting

2/3

758

Europe, Canada, Japan, US, RoW

Cobolimab, Dostarlimab, Docetaxel

GlaxoSmithKline

Lung Cancer, Non-Small Cell

10/24

10/25

PURITY, NCT06037980: CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Recruiting

2/3

300

Europe

Gemcitabine, Nab paclitaxel, Abraxane, Cisplatin, Curative Surgery, Capecitabine

Gruppo Oncologico del Nord-Ovest

Biliary Tract Cancer, Cholangiocarcinoma

12/28

01/29

SENECA, NCT03387592 / 2016-000767-17: CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

Recruiting

112

Europe

CPT-11, Calcio levofolinate, 5-Fluorouracil, Capecitabine, Temozolomide

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Neuroendocrine Carcinoma

01/22

BEAT, NCT03896074 / 2018-003973-82: Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients

Not yet recruiting

206

Europe

Atezolizumab, Bevacizumab

Fondazione Ricerca Traslazionale

Non-small-cell Lung Cancer Patients

05/22

04/23

HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting

Europe

Abemaciclib, Aromatase Inhibitors

University of Milano Bicocca

Advanced Breast Cancer

12/23

ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting

400

Europe

Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib

Fondazione per la Medicina Personalizzata

Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer

12/24

06/25

CAVE 2, NCT05291156: CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Recruiting

173

Europe

Cetuximab, Erbitux, Avelumab, Bavencio

University of Campania "Luigi Vanvitelli"

Metastatic Colorectal Cancer

07/25

PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting

220

Europe

Giredestrant, Triptorelin, Anastrozole

ETOP IBCSG Partners Foundation, Hoffmann-La Roche

Breast Cancer

06/26

REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

	Data from a trial for NSCLC
	Jan 2022 - Jan 2022: Data from a trial for NSCLC

Recruiting

1/2

284

Europe, Japan, US, RoW

CLN-081, TAS6417; zipalertinib

Cullinan Therapeutics Inc.

Non Small Cell Lung Cancer, EGFR Exon 20 Mutation

12/24

ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting

1/2

359

Europe, Canada, Japan, US, RoW

NVL-520

Nuvalent Inc., Nuvalent, Inc.

Locally Advanced Solid Tumor, Metastatic Solid Tumor

10/25

10/26

NCT03850067: A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer

Active, not recruiting

Europe

CC-90011, Cisplatin, Carboplatin, Etoposide, Nivolumab

Celgene

Small Cell Lung Carcinoma

06/24

NCT04901806: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Terminated

Europe, US, RoW

PBI-200

Pyramid Biosciences

Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor

07/23

ELVN-002-001, NCT05650879: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Recruiting

198

Europe, US, RoW

ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1

Enliven Therapeutics

HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification

07/26

HERMIONE-13, NCT05173103: Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Recruiting

N/A

150

Europe

University of Milano Bicocca

Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer

01/24

NCT06235268: Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma

Recruiting

N/A

1000

Europe

Active systemic or non-systemic treatment (palliative or observation procedure)

Federation of Italian Cooperative Oncology Groups

Carcinoma, Urothelial

11/25

NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting

N/A

300

Europe

Trastuzumab emtansine

Consorzio Oncotech, Roche Pharma AG

Breast Cancer

09/24

05/25

I-STOP, NCT05418660: Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Recruiting

N/A

300

Europe

Immunotherapy, Nivolumab, Pembrolizumab, Atezolizumab

University of Milano Bicocca, Azienda Ospedaliera San Gerardo di Monza

Non-small Cell Lung Cancer

11/24

RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting

N/A

3000

Europe

Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.

Solid Tumours in Advanced Stages

10/26

NCT04282083: Protocol ITANET - Registry

Recruiting

N/A

3600

Europe

Italian Association Neuroendocrine Tumors

Gastro-entero Pancreatic Neuroendocrine Tumors

07/27

07/32

NCT05550961: APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Recruiting

N/A

1200

Europe

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Politecnico di Milano, Ospedale Policlinico San Martino, Insieme per i Pazienti di Oncologia Polmonare Onlus (IPOP), ASST Grande Ospedale Metropolitano Niguarda, University of Campania "Luigi Vanvitelli", Azienda Ospedaliera dei Colli, Fondazione IRCCS Policlinico San Matteo di Pavia, Azienda Ospedaliera S. Maria della Misericordia, Azienda Ospedaliera "Sant'Andrea", Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy, IRCCS Sacro Cuore Don Calabria di Negrar, Azienda Ospedaliero, Universitaria Ospedali Riuniti, Istituto Clinico Humanitas, Azienda Unità Sanitaria Locale della Romagna, Istituti Ospitalieri di Cremona

NSCLC, Cancer, Lung Cancer, Adenocarcinoma of Lung, Squamous Cell Lung Cancer

10/27

10/32

Pape, Lars

Pro-Tac, NCT06057545: Pharmacokinetics, Effectiveness and Tolerability of Prolonged-release Tacrolimus After Paediatric Kidney Transplantation

Recruiting

Europe

Envarsus®, Prograf

University Hospital, Essen

Pediatric Kidney Disease

12/24

03/25

smartNTx, NCT05897047: Prospective, Randomized Controlled Trial

Recruiting

N/A

384

Europe

Additional interventional telemedical management

University of Erlangen-Nürnberg Medical School, Charite University, Berlin, Germany, University Hospital, Essen

Kidney Transplant Rejection

04/25

FOrMe, NCT03949972: The Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)

Recruiting

N/A

500

Europe

Biosampling

Prof. Dr. Paul Brinkkoetter, German Research Foundation, Medical Faculty and the Faculty of Natural Sciences of the University of Cologne, Cluster of Excellence on Cellular Stress Responses in Ageing-Associated Diseases, Cologne Center for Genomics

Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Idiopathic Nephrotic Syndrome

03/28

03/33

Vogel-Claussen, Jens

FUNLUM, NCT04512521: Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic Asthma

Recruiting

N/A

Europe

Mepolizumab

Hannover Medical School, GlaxoSmithKline

Asthma; Eosinophilic

02/25

08/25

HANSE, NCT04913155: - Holistic Implementation Study Assessing a Northern German Interdisciplinary Lung Cancer Screening Effort

Recruiting

N/A

12100

Europe

Low-dose CT screening

Hannover Medical School, LungenClinic Grosshansdorf, University Hospital Schleswig-Holstein, German Center for Lung Research

Lung Cancer

06/26

01/28

Hollebecque, Antoine

OSCAR, NCT02885753: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

Recruiting

348

Europe

Oxaliplatin intravenous, Oxaliplatin IV, 5 FU bolus, 5 FU, Folinic acid, Folinic Acid IV, Oxaliplatin intra-arteriel, Oxaliplatin IA, Panitumumab, Pani, Bevacizumab, Beva, 5 FU continuous, Irinotecan, IRI

Federation Francophone de Cancerologie Digestive

Colorectal Neoplasms

09/25

09/27

FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting

200

Europe, US, RoW

Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice

TransThera Sciences (Nanjing), Inc.

Cholangiocarcinoma

05/26

08/26

SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting

800

Europe

Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine

UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament

Biliary Tract Neoplasms

06/27

06/28

NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Recruiting

250

Europe, Canada, Japan, US, RoW

zenocutuzumab (MCLA-128), bispecific, MCLA-128

Merus N.V.

Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion

12/26

SURPASS-2, NCT04752358 / 2020-005802-24: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers

Terminated

Europe, Canada, US

Autologous genetically modified ADP-A2M4CD8 cells

Adaptimmune, ICON plc

Esophageal Cancer, Esophagogastric Junction Cancer

06/23

12/23

MCLA-158-CL01, NCT03526835: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Recruiting

1/2

360

Europe, US

MCLA-158, petosemtamab, MCLA-158 +Pembrolizumab

Merus N.V., Chiltern International Inc., Q2 Solutions, Oncology Therapeutic Development (OTD), 4Clinics

Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma

06/24

06/25

PanC-ASAP, NCT04431258: ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

Completed

1/2

150

Europe, US, RoW

ABTL0812, Folfirinox, Chemotherapy, Placebo

Ability Pharmaceuticals SL

Pancreatic Cancer

01/24



	Diseases Companies Products Productz Mechanisms of Action Sites